{
    "clinical_study": {
        "@rank": "8162", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "oral sitagliptin 100 mg on day 6 after administration of placebo (30 mg per day) for 6 days"
            }, 
            {
                "arm_group_label": "Combination of  lansoprazole and sitagliptin", 
                "arm_group_type": "Experimental", 
                "description": "oral sitagliptin 100 mg on day 6 after administration of lansoprazole (30 mg per day) for 6 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Oral hypoglycemic medications sometimes do not control type 2 diabetes well. Proton pump\n      inhibitors (PPIs) as adjunctive therapy might improve diabetes control and could enhance the\n      hypoglycemic activity of DPP4, but there is little clinical data on efficacy of this\n      therapeutic strategy. The investigators sought to examine the effect of PPI lansoprazole,\n      DPP-4 inhibitor sitagliptin, and their combination therapy on insulin and glucose regulation\n      in healthy subjects in oral glucose tolerance (OGTT)."
        }, 
        "brief_title": "Effects of Lansoprazole on Sitagliptin Glucose-lowering Ability in Healthy Males: a Randomised Crossover Study", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Oral hypoglycemic medications sometimes do not control type 2 diabetes well. Proton pump\n      inhibitors (PPIs) as adjunctive therapy might improve diabetes control and could enhance the\n      hypoglycemic activity of DPP4, but there is little clinical data on efficacy of this\n      therapeutic strategy. We sought to examine the effect of PPI (lansoprazole), DPP4\n      (sitagliptin), and their combination therapy on insulin and glucose regulation in healthy\n      subjects in oral glucose tolerance (OGTT)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  General good health condition\n\n          -  Male subject, between 18 and 50 years\n\n        Exclusion Criteria\n\n          -  Overweight (Body Mass Index \u226530)\n\n          -  Metabolic disorders\n\n          -  History of gastrointestinal disorders\n\n          -  Regular (daily) intake of medication\n\n          -  Smoking more than 10 cigarettes/day\n\n          -  History of drug abuse\n\n          -  Exhaustive (> 3 units/day) alcohol consumption\n\n          -  Exhaustive (> 5 units/day) caffeine consumption (coffee, tea, cola, or other\n             caffeine based drinks)\n\n          -  Recent (in the last 14 days) donation of blood\n\n          -  Recent (in the last 2 days) donation of blood plasma\n\n          -  Participation in another trial within 4 weeks before the start of the study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820104", 
            "org_study_id": "20130301"
        }, 
        "intervention": {
            "arm_group_label": "Combination of  lansoprazole and sitagliptin", 
            "intervention_name": "lansoprazole, 30 mg per day for 6 days", 
            "intervention_type": "Drug", 
            "other_name": "Oral glucose tolerance test (OGTT)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Lansoprazole", 
                "Sitagliptin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Xi'an", 
                    "country": "China", 
                    "state": "Shaanxi"
                }, 
                "name": "Department of pharmacy, Xijing Hospital, Fourth Military Medical University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Lansoprazole on Sitagliptin Glucose-lowering Ability in Healthy Males", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Glucose Tolerance", 
            "safety_issue": "No", 
            "time_frame": "0, 15, 30, 60, 90, 120, 180 min. after glucose administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820104"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Plasma insulin and C-peptide concentrations during oral glucose tolerance test", 
            "safety_issue": "No", 
            "time_frame": "0, 15, 30, 60, 90, 120, 180 min. after glucose administration"
        }, 
        "source": "Xijing Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xijing Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}